IVA

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $360k65k shares AddQ1 2026 $292k $5.55 $4.62
Ken GriffinCitadel Advisors $-73.0K ExitQ3 2025 $73k -- $4.62

News

globenewswire.comInventiva Announces Trading Resumption of its Ordinary Shares on Euronext Parisglobenewswire.comJun 2

globenewswire.comInventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readoutglobenewswire.comJun 2

globenewswire.comInventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Parisglobenewswire.comJun 2

globenewswire.comInventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Parisglobenewswire.comJun 2

globenewswire.comInventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Parisglobenewswire.comJun 2

Trade IVA

About Inventiva S.A.

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.

CEO: Andrew Obenshain
IPO Date: Jul 10, 2020

Market Data

Open: $4.00
High: $4.02
Low: $3.70
Volume: 972.9K
52W High: $7.98
52W Low: $2.85

Valuation

Market Cap: $206.4M
Enterprise Value: $413.2M

Financials

Free Cash Flow: -$101.2M
Revenue: $4.5M
Net Income: -$340.2M
Cash: $99.3M
Debt: $59.4M

Events

EarningsSep 25

EPS est. -0.42758